International Journal of Cardiology
Papers 31621
1 page of 3,163 pages (31.6k results)
#1Arwa Younis (URMC: University of Rochester Medical Center)
#2Ilan Goldenberg (URMC: University of Rochester Medical Center)H-Index: 58
#1Amar Trivedi (NU: Northwestern University)H-Index: 2
#2Jacob Hoffman (NU: Northwestern University)
Last.Rishi Arora (NU: Northwestern University)H-Index: 18
view all 3 authors...
Abstract In this review we examine the current state of gene therapy for the treatment of cardiac arrhythmias. We describe advances and challenges in successfully creating and incorporating gene vectors into the myocardium. After summarizing the current scientific research in gene transfer technology we then focus on the most promising areas of gene therapy, the treatment of atrial fibrillation and ventricular tachyarrhythmias. We review the scientific literature to determine how gene therapy co...
#1Nicolas DumonteilH-Index: 26
#2Christian Juhl Terkelsen (Aarhus University Hospital)H-Index: 38
Last.Thierry LefèvreH-Index: 61
view all 12 authors...
Abstract Aims To investigate the impact of transcatheter aortic valve replacement (TAVR) without preliminary balloon aortic valvuloplasty (pre-BAV) on periprocedural outcomes in a large, real-world registry. Methods and results The SOURCE 3 registry was an observational, multi-center, single-arm study of patients with severe, symptomatic aortic stenosis at high surgical risk treated with the SAPIEN 3 transcatheter heart valve (THV). Procedural and 30-day outcomes were compared between two groups...
2 CitationsSource
#1Giuseppe Vergaro (Sant'Anna School of Advanced Studies)H-Index: 14
#2Alberto AimoH-Index: 7
Last.Michele Emdin (Sant'Anna School of Advanced Studies)H-Index: 47
view all 14 authors...
Abstract Background Evidence of sympathetic and renin-angiotensin-aldosterone system activation provided a rationale for neurohormonal antagonism in heart failure with reduced ejection fraction (HFrEF), while no data are available in patients with milder degree of systolic dysfunction. We aimed to investigate neurohormonal function in HF with preserved and mid-range EF (HFpEF/HFmrEF). Methods Three cohorts (n = 189/each) of stable HFpEF, HFmrEF and HFrEF patients were selected (median age 70, 67...
1 CitationsSource
#1Yi-Ping Hung (NYMU: National Yang-Ming University)H-Index: 6
#2Yu-Wen Hu (NYMU: National Yang-Ming University)H-Index: 12
Last.Tze-Fan Chao (NYMU: National Yang-Ming University)H-Index: 31
view all 14 authors...
Abstract Aims Patients with atrial fibrillation (AF) may be at higher risk for cancer, possibly due to the presence of coexisting risk factors. In this study, we investigate the magnitude and predictors of this potential risk within a population-based study. Methods and results The study cohort included 332,555 AF patients aged ≥20 years without past history of cancer. Standardized incidence ratio (SIR) was used as a measure of relative risk, comparing observed cancer incidence among patients wi...
#1Debora Junqueira (UNIFESP: Federal University of São Paulo)
#2Mark Y. Chan (NUS: National University of Singapore)H-Index: 21
Last.Leonardo P. de Carvalho (UNIFESP: Federal University of São Paulo)H-Index: 6
view all 3 authors...
#1Xiaoyun Liu (SJTU: Shanghai Jiao Tong University)
#2Shasha Zhang (SJTU: Shanghai Jiao Tong University)H-Index: 2
Last.Hongxin Zhu (SJTU: Shanghai Jiao Tong University)H-Index: 5
view all 10 authors...
Abstract Background The therapeutic potential of doxorubicin (DOX) is limited by cardiotoxicity. Rubicon is an inhibitory interacting partner of autophagy protein UVRAG. Currently, the role of Rubicon in DOX-induced cardiotoxicity is unknown. In this study, we test the hypothesis that loss of Rubicon attenuates DOX-induced cardiotoxicity. Methods A mouse model of acute DOX-induced cardiotoxicity was established by a single intraperitoneal injection of DOX at a dose of 20 mg/kg. Rubicon expressio...
#1Susanne J. Maurer (TUM: Technische Universität München)H-Index: 1
#2Oktay Tutarel (TUM: Technische Universität München)H-Index: 15
#1Joel Ohm (KI: Karolinska Institutet)H-Index: 1
#2Paul Hjemdahl (KI: Karolinska Institutet)H-Index: 55
Last.Per H. Svensson (KI: Karolinska Institutet)H-Index: 14
view all 8 authors...
Abstract Background Low density lipoprotein cholesterol (LDL-C) goals post-myocardial infarction (MI) are debated, and the significance of achieved blood lipid levels for predicting a first recurrent atherosclerotic cardiovascular disease (rASCVD) event post-MI is unclear. Methods This was a cohort study on first-ever MI survivors aged ≤76 years attending 4–14 week revisits throughout Sweden 2005–2013. Personal-level data was collected from SWEDEHEART and linked national registries. Exposures we...
1 CitationsSource
#1Anwar J. Siddiqui (KI: Karolinska Institutet)H-Index: 11
#2Martin J. Holzmann (KI: Karolinska Institutet)H-Index: 18
Abstract Objectives We sought to investigate the association between LVEF and clinical outcomes after NSTEMI, and the benefit of guideline-recommended pharmacotherapy in elderly patients. Background New-onset reduction in LVEF is common after NSTEMI in patients of advanced age. There is little information about outcomes in relation to LVEF, and the benefit of guideline-recommended pharmacotherapy in elderly patients. Materials and methods The SWEDEHEART registry was used to identify all patients...
Top fields of study
Heart failure
Myocardial infarction
Diabetes mellitus